Structure Therapeutics (GPCR) Stock Price, Quote, News & History

Q: What sector and industry does Structure Therapeutics (GPCR) operate in?

Structure Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Comments

Structure Therapeutics (GPCR) Stock Price, Quote, News & History

GPCRNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$88.45

1.301.49%

At close: Jan 30, 4:00 PM EST

$88.06

-0.39-0.44%

After Hours: 7:42 PM EST

Overview

News Earnings Options Analyst Ratings Short Interest Government Trades Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$87.15

Close

$88.45

Volume / Avg.

789.92K / 1.59M

Day Range

$86.67 - $90.24

52 Wk Range

13.22 - 94.90

Market Cap

$6.22B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

68

Short Interest

11.41%

Days to Cover

5.47

Recent Structure Therapeutics Inc News

Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It

Structure Therapeutics CEO discusses oral GLP-1 strategy, Phase 3 plans, and why pills and combination therapies may reshape obesity treatment.

Vandana Singh

Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its experimental pill to market.

Vandana Singh

Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-194.25M

Investing Cash Flow (TTM)

66.89M

Financing Cash Flow (TTM)

58.14M

Free Cash Flow (TTM)

-196.38M

Capital Expenditure (TTM)

-2.13M

Net Change in Cash (TTM)

-69.22M

Analyst Trends and Forecast

2

Aug 25

6

Dec 25

2

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.46B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

7.99

Earnings Yield % (TTM)

-4.20%

Earnings Yield % (FWD)

-4.41%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$10.90

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$102.91M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$87.15

Close

$88.45

Volume / Avg.

789.92K / 1.59M

Day Range

$86.67 - $90.24

52 Wk Range

13.22 - 94.90

Market Cap

$6.22B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

68

Short Interest

11.41%

Days to Cover

5.47

About

Sector

Health Care

Industry

Pharmaceuticals

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both struc...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Structure Therapeutics (GPCR) stock?

A

You can purchase shares of Structure Therapeutics (NASDAQ:GPCR) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Structure Therapeutics (GPCR) competitors?

A

Other companies in Structure Therapeutics’s space includes: Novo Nordisk AS (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and Haleon PLC (NYSE:HLN).

Q

What is the forecast, or price target, for Structure Therapeutics (GPCR) stock?

A

Structure Therapeutics has a consensus price target of $96.31.

Q

What is the current price for Structure Therapeutics (GPCR)?

A

The stock price for Structure Therapeutics (NASDAQ: GPCR) is $88.0643 last updated January 30, 2026 at 7:42 PM EST.

Q

Does Structure Therapeutics (GPCR) pay a dividend?

A

There are no upcoming dividends for Structure Therapeutics.

Q

When is Structure Therapeutics (NASDAQ:GPCR) reporting earnings?

A

Structure Therapeutics does not have any upcoming earnings scheduled.

Q

Is Structure Therapeutics (GPCR) going to split?

A

There is no upcoming split for Structure Therapeutics.

Q

What sector and industry does Structure Therapeutics (GPCR) operate in?

A

Structure Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Axsome Therapeutics Inc

NASDAQ:AXSM

$181.22

-1.65%

Jazz Pharmaceuticals PLC

NASDAQ:JAZZ

$164.49

%

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$87.15

Close

$88.45

Volume / Avg.

789.92K / 1.59M

Day Range

$86.67 - $90.24

52 Wk Range

13.22 - 94.90

Market Cap

$6.22B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

68

Short Interest

11.41%

Days to Cover

5.47

Recent Structure Therapeutics Inc News

Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It

Structure Therapeutics CEO discusses oral GLP-1 strategy, Phase 3 plans, and why pills and combination therapies may reshape obesity treatment.

Vandana Singh

Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its experimental pill to market.

Vandana Singh

Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-194.25M

Investing Cash Flow (TTM)

66.89M

Financing Cash Flow (TTM)

58.14M

Free Cash Flow (TTM)

-196.38M

Capital Expenditure (TTM)

-2.13M

Net Change in Cash (TTM)

-69.22M

Analyst Trends and Forecast

2

Aug 25

6

Dec 25

2

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$5.46B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

7.99

Earnings Yield % (TTM)

-4.20%

Earnings Yield % (FWD)

-4.41%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$10.90

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$102.91M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$87.15

Close

$88.45

Volume / Avg.

789.92K / 1.59M

Day Range

$86.67 - $90.24

52 Wk Range

13.22 - 94.90

Market Cap

$6.22B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

68

Short Interest

11.41%

Days to Cover

5.47

About

Sector

Health Care

Industry

Pharmaceuticals

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both struc...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry